Article
Oncology
Mirella L. Altoe, Kevin Kalinsky, Alessandro Marone, Hyun K. Kim, Hua Guo, Hanina Hibshoosh, Mariella Tejada, Katherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Dawn L. Hershman, Andreas H. Hielscher
Summary: This study evaluates changes in optically derived parameters in breast cancer patients undergoing neoadjuvant chemotherapy, finding that certain parameters are associated with treatment response and may predict early response to neoadjuvant chemotherapy.
CLINICAL CANCER RESEARCH
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wenhong Jiang, Siyao Du, Si Gao, Lizhi Xie, Zichuan Xie, Mengfan Wang, Can Peng, Jing Shi, Lina Zhang
Summary: There is a correlation between syMRI relaxometry and ADC maps in different breast cancer subtypes and treatment response subgroups. The correlation is more significant in triple-negative breast cancer (TNBC) and less significant in HER2-positive breast cancer. T2 maps show a higher correlation with ADC in luminal HER2-negative breast cancer.
INSIGHTS INTO IMAGING
(2023)
Review
Immunology
Kshitij Wagh, Michael S. Seaman
Summary: Combining broadly neutralizing antibodies (bNAbs) and multispecific therapeutics has the potential to effectively prevent and treat HIV-1 infection. Recent clinical studies have shown that the complementarity of bNAbs can overcome resistance mutations and viral diversity, leading to successful prophylactic and therapeutic strategies. Therefore, next-generation bNAb-based combination or multispecific therapeutics should leverage the complementarity of component bNAbs to maximize potency and breadth for clinical success.
CURRENT OPINION IN HIV AND AIDS
(2023)
Article
Oncology
Monika Graeser, Nadia Harbeck, Oleg Gluz, Rachel Wuerstlein, Christine zu Eulenburg, Claudia Schumacher, Eva -Maria Grischke, Helmut Forstbauer, Moritz Dimpfl, Michael Braun, Matthias Christgen, Hans Heinrich Kreipe, Jochem Potenberg, Raquel von Schumann, Bahriye Aktas, Cornelia Kolberg-Liedtke, Sherko Kuemmel, Ulrike Nitz
Summary: Breast ultrasound performed during neoadjuvant therapy can predict the pathologic complete response in breast cancer patients. Tumor subtype and changes in lesion dimension on ultrasound were identified as parameters associated with pathologic complete response.
Editorial Material
Oncology
Carsten Denkert, Sibylle Loibl
Summary: The therapeutic landscape of breast cancer is complex. A breast cancer classification scheme has been proposed in this study, which can predict treatment response more accurately and continuously adapt to guide prioritization of new treatments.
Article
Hospitality, Leisure, Sport & Tourism
Richard Sharpley
Summary: The paper argues that the main issue with achieving sustainable tourism lies in the continuation of an economic growth model and suggests adopting sustainable consumption levels as a solution. However, even among environmentally aware post-millennial generation, voluntary limiting of tourism consumption is unlikely. Therefore, the path to sustainable tourism production and consumption lies in effective regulation.
Review
Oncology
Sayali S. Onkar, Neil M. Carleton, Peter C. Lucas, Tullia C. Bruno, Adrian V. Lee, Dario A. A. Vignali, Steffi Oesterreich
Summary: Breast cancer is a diverse disease with different subtypes, and recent advances have provided new insights into the complex interactions between tumor and immune cells. While immunotherapy has shown limited promise for breast cancer, this review aims to identify opportunities for tailored immunotherapy agents based on the specific features of each breast cancer subtype.
Article
Oncology
Svenja Kemmer, Mireia Berdiel-Acer, Eileen Reinz, Johanna Sonntag, Nooraldeen Tarade, Stephan Bernhardt, Mirjam Fehling-Kaschek, Max Hasmann, Ulrike Korf, Stefan Wiemann, Jens Timmer
Summary: Breast cancer subtypes differ in their treatment and prognosis due to the expression and activity of different receptors. The HER2 subtype has been successfully targeted with anti-HER2 therapies, and this study explores whether the HER2 receptor and downstream signaling network could be potential therapeutic targets beyond the HER2-positive subtype. The findings suggest that major parts of the intracellular signal transduction network are unchanged between subtypes, and alterations in this network could render anti-HER therapies relevant beyond the HER2-positive subtype.
Article
Health Care Sciences & Services
Liliana Ascione, Paola Zagami, Eleonora Nicolo, Edoardo Crimini, Giuseppe Curigliano, Carmen Criscitiello
Summary: The PI3K pathway plays a key role in cancer, and PIK3CA mutations are common in breast cancer. The role of PI3K inhibition in different breast cancer subtypes is not well established. Alpelisib is an effective drug for treating breast cancer with specific mutations. This review summarizes the clinical evidence of PIK3CA mutations in different breast cancer subtypes and the clinical trials investigating PI3Ki.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Monika Graeser, Simone Schrading, Oleg Gluz, Kevin Strobel, Rachel Wuerstlein, Sherko Kuemmel, Claudia Schumacher, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Matthias Christgen, Jascha Adams, Henrik Nitzsche, Marianne Just, Hans Holger Fischer, Bahriye Aktas, Jochem Potenberg, Raquel Von Schumann, Cornelia Kolberg-Liedtke, Nadia Harbeck, Christiane K. Kuhl, Ulrike Nitz
Summary: Early response assessed by ultrasound, MRI and Ki-67 is a strong predictor for pathologic complete response (pCR) in breast cancer patients. The predictive value varies among different subtypes, with MRI and Ki-67 performing better than ultrasound in HR-/HER2+ tumors. Adding MRI+/-Ki-67 did not significantly improve pCR prediction in most patients.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Hiroko Masuda, Kenichi Harano, Sakiko Miura, Ying Wang, Yuko Hirota, Oi Harada, Mohit Kumar Jolly, Yuki Matsunaga, Bora Lim, Anita L. Wood, Napa Parinyanitikul, Hee Jin Lee, Gyungyub Gong, Jason T. George, Herbert Levine, Jangsoon Lee, Xiaoping Wang, Anthony Lucci, Arvind Rao, Brock L. Schweitzer, O. Rayne Lawrence, Robert S. Seitz, Stephan W. Morris, David R. Hout, Seigo Nakamura, Savitri Krishnamurthy, Naoto T. Ueno
Summary: The study found that TNBC molecular subtype and IM signature frequently change after NST, and the results suggest that EMT is promoted in the changed subtypes.
JCO PRECISION ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
M. Matsuda, N. Fukuyama, T. Matsuda, S. Kikuchi, Y. Shiraishi, Y. Takimoto, Y. Kamei, M. Kurata, R. Kitazawa, T. Kido
Summary: Synthetic MRI was used to predict pathological complete response in breast cancers after neoadjuvant chemotherapy, with SD of Pre-T2 being a significant and independent predictor of pCR. The results suggest potential for clinical application pending further verification.
CLINICAL RADIOLOGY
(2022)
Review
Oncology
Emily A. Kolyvas, Carlos Caldas, Kathleen Kelly, Saif S. Ahmad
Summary: Breast cancer is a common and deadly cancer, and the role of AR in this type of cancer is still not fully understood. However, targeting AR in breast cancer may have therapeutic potential and further research is needed for effective treatment.
BREAST CANCER RESEARCH
(2022)
Review
Pharmacology & Pharmacy
Hanyi Fang, Alessandra Cavaliere, Ziqi Li, Yiyun Huang, Bernadette Marquez-Nostra
Summary: Breast cancer, the most common cancer in women globally, presents challenges in diagnosis and treatment due to its heterogeneity and drug resistance. Molecular imaging methods offer precision medicine tools, while new therapeutic targets and options are being developed to overcome resistance to standard treatments for breast cancer patients.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa Gallagher, Pei Rong Evelyn Lee, Zelos Zhu, Mark J. Magbanua, Rosalyn Sayaman, Nicholas O'Grady, Amrita Basu, Amy Delson, Jean Philippe Coppe, Ruixiao Lu, Jerome Braun, Smita M. Asare, Laura Sit, Jeffrey B. Matthews, Jane Perlmutter, Nola Hylton, Minetta C. Liu, Paula Pohlmann, W. Fraser Symmans, Hope S. Rugo, Claudine Isaacs, Angela M. DeMichele, Douglas Yee, Donald A. Berry, Lajos Pusztai, Emanuel F. Petricoin, Gillian L. Hirst, Laura J. Esserman, Laura J. van 't Veer
Summary: By incorporating gene expression, protein/phosphoprotein, and clinical data, we have created new breast cancer subtypes that can better predict drug responses. The best performing subtypes include Immune, DNA repair, and HER2/Luminal phenotypes. Treatment allocation based on these subtypes significantly increases the overall pathologic complete response rate. This study is important for guiding future breast cancer treatment.
Article
Oncology
Clementine Jankowski, S. Guiu, M. Cortet, C. Charon-Barra, I. Desmoulins, V. Lorgis, L. Arnould, P. Fumoleau, B. Coudert, R. Rouzier, C. Coutant, F. Reyal
BREAST CANCER RESEARCH AND TREATMENT
(2017)
Article
Oncology
Roman Rouzier, Sebastien Gouy, Frederic Selle, Eric Lambaudie, Anne Floquet, Virginie Fourchotte, Christophe Pomel, Pierre-Emmanuel Colombo, Elsa Kalbacher, Sandrine Martin-Francoise, Raffaele Fauvet, Philippe Follana, Anne Lesoin, Fabrice Lecuru, Youssef Ghazi, Julien Dupin, Elisabeth Chereau, Sarah Zohar, Paul Cottu, Florence Joly
EUROPEAN JOURNAL OF CANCER
(2017)
Article
Oncology
Julien Seror, Aurelie Roulot, Eugenie Guillot, Roman Rouzier
GYNECOLOGIC ONCOLOGY
(2017)
Article
Oncology
Laure Chenoz, Juliette Phelippeau, Emmanuel Barranger, Nicolas Bourdel, Jean Luc Brun, Elisabeth Chereau, Pierre Collinet, Charles Coutant, Emile Darai, Xavier Deffieux, Tristan Gautier, Francois Golfier, Cyrille Huchon, Lobna Ouldamer, Roman Rouzier, Martin Koskas
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2017)
Review
Oncology
Maaike H. M. Oonk, Francois Planchamp, Peter Baldwin, Mariusz Bidzinski, Mats Brannstrom, Fabio Landoni, Sven Mahner, Umesh Mahantshetty, Mansoor Mirza, Cordula Petersen, Denis Querleu, Sigrid Regauer, Lukas Rob, Roman Rouzier, Elena Ulrikh, Jacobus van der Velden, Ignace Vergote, Linn Woelber, Ate G. J. van der Zee
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2017)
Article
Pathology
Marion Lavigne, Emmanuelle Menet, Jean-Christophe Tille, Marick Lae, Laetitia Fuhrmann, Claire Bonneau, Gabrielle Deniziaut, Samia Melaabi, Charlotte C. K. Ng, Caterina Marchio, Roman Rouzier, Ivan Bieche, Anne Vincent-Salomon
Letter
Oncology
Alexandre Yazigi, Celine Callens, Aude Jaillot, Florence Lerebours, Jean-Marc Guinebretiere, Roman Rouzier, Delphine Hequet
BULLETIN DU CANCER
(2017)
Review
Oncology
Martha Duraes, Eugenie Guillot, Julien Seror, Nicolas Pouget, Roman Rouzier
BULLETIN DU CANCER
(2017)
Article
Oncology
A. -S. Hamy, J. -Y. Pierga, A. Sabaila, E. Laas, H. Bonsang-Kitzis, C. Laurent, A. Vincent-Salomon, P. Cottu, F. Lerebours, R. Rouzier, M. Lae, F. Reyal
ANNALS OF ONCOLOGY
(2017)
Article
Oncology
Matti Aapro, Michelino De Laurentiis, Dan Rea, Juan Enrique Bargallo Rocha, Roberto Elizalde, Laszlo Landherr, Barbro Linderholm, Eleftherios Mamounas, Christos Markopoulos, Patrick Neven, Alexander Petrovsky, Roman Rouzier, Vincent Smit, Christer Svedman, Daniel Schneider, Christoph Thomssen, Miguel Martin
Article
Oncology
Delphine Hequet, Cyrille Huchon, Sandrine Baffert, Severine Alran, Fabien Reyal, Thuy Nguyen, Alix Combes, Caroline Trichot, Karine Alves, Helene Berseneff, Roman Rouzier
BRITISH JOURNAL OF CANCER
(2017)
Article
Oncology
Laura Vincent, Francois Margueritte, Jennifer Uzan, Clementine Owen, Julien Seror, Nicolas Pouget, Eugenie Guillot, Roman Rouzier
BULLETIN DU CANCER
(2017)
Article
Oncology
Delphine Hequet, Slim Mzoughi, Roman Rouzier, Ernesto Guccione
BULLETIN DU CANCER
(2017)
Article
Oncology
Alexandre de Nonneville, Anthony Goncalves, Christophe Zemmour, Jean M. Classe, Monique Cohen, Eric Lambaudie, Fabien Reyal, Christophe Scherer, Xavier Muracciole, Pierre E. Colombo, Sylvia Giard, Roman Rouzier, Richard Villet, Nicolas Chopin, Emile Darai, Jean R. Garbay, Pierre Gimbergues, Laura Sabiani, Charles Coutant, Renaud Sabatier, Francois Bertucci, Jean M. Boher, Gilles Houvenaeghel
BREAST CANCER RESEARCH AND TREATMENT
(2017)
Article
Oncology
Roman Rouzier, Catherine Uzan, Alexandra Rousseau, Eugenie Guillot, Sonia Zilberman, Charles Meyer, Pablo Estevez, Pierre-Francois Dupre, David Kere, Virginie Doridot, Gauthier D'halluin, Xavier Fritel, Nicolas Pouget, Clementine Jankowski, Chafika Mazouni, Tabassome Simon, Charles Coutant
BRITISH JOURNAL OF CANCER
(2017)
